|
|
Effects of oral Baitouweng Decoction combined with Mesalazine enema in the treatment of ulcerative colitis |
NIE Zhenjing SHEN Wenjing YAO Rui WANG Xinlei |
Department of Gastroenterology, Fengrun People’s Hospital of Tangshan City, Hebei Province, Tangshan 064000, China |
|
|
Abstract Objective To analyze the effects of oral Baitouweng Decoction combined with Mesalazine enema in the treatment of ulcerative colitis (UC). Methods One hundred and twenty patients with UC admitted to Fengrun People’s Hospital of Tangshan City from January 2017 to May 2019 were divided into control group and treatment group according to the random number table method, with 60 cases in each group. The control group was treated with Mesalazine enema, while the treatment group was treated with oral Baitouweng Decoction on the basis of the control group, with 12 weeks of treatment course. The TCM symptom scores, peripheral immune function, humoral immunity level, serum inflammatory factor levels, inflammatory bowel disease questionnaire (IBDQ) before and after treatment were compared between the two groups, and the adverse reactions during treatment were recorded. Results After treatment, the TCM symptom scores, CD8+, IgM, IgA and IgG, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) and interleukin-8 (IL-8) in the two groups were lower than those before treatment, which in the treatment group were significantly lower than those in the control group (all P < 0.05); the CD4+, natural killer cells (NK cells), CD4+/CD8+, the scores of IBDQ in the two groups were higher than those before treatment, which in the treatment group were significantly higher than those in the control group (all P < 0.05). No obvious adverse reactions occurred during the treatment of the two groups. Conclusion The efficacy of oral Baitouweng Decoction combined with Mesalazine enema in the treatment of UC is better than single-agent Mesalamine enema, and the safety is good.
|
|
|
|
|
[1] 张露,沈洪,叶柏,等.525例溃疡性结肠炎患者临床特征分析[J].世界科学技术:中医药现代化,2018,20(4):574-578.
[2] 苑克丽,唐彤宇,陈晓敏,等.吸烟对于溃疡性结肠炎保护性机制的研究进展[J].安徽医学,2017,39(11):1412-1414.
[3] 牟海军,陈幸幸,周光群,等.美沙拉嗪肠溶片治疗激素抵抗型重症溃疡性结肠炎的临床研究[J].中国临床药理学杂志,2016,32(21):1950-1952.
[4] 李秋梅,田志颖.丹参酮ⅡA注射液联合美沙拉嗪肠溶片治疗溃疡性结肠炎患者的临床研究[J].中国临床药理学杂志,2019,35(14):1425-1427.
[5] 沈洪,邢敬.中西医结合治疗溃疡性结肠炎的优势及临床应用[J].医学研究生学报,2019,32(6):586-590.
[6] 赵振营.溃疡性结肠炎中药组方规律及整合药理学分子机制探索[J].中草药,2018,49(13):3042-3050.
[7] 刘史佳,吕翔宇,熊玥,等.基于液质联用技术的白头翁汤治疗溃疡性结肠炎小鼠血清代谢组学分析[J].南京中医药大学学报,2019,35(5):535-540.
[8] 王晓妹,田歌,段强军,等.白头翁汤正丁醇提取物对白念珠菌定植下溃疡性结肠炎小鼠的作用机制研究[J].中国中药杂志,2018,43(14):2979-2984.
[9] 中国中西医结合学会消化系统疾病专业委员会.溃疡性结肠炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(2):105-111.
[10] 张声生,沈洪,郑凯,等.溃疡性结肠炎中医诊疗专家共识意见(2017)[J].中华中医药杂志,2017,32(8):267-271.
[11] 叶益平.白头翁汤治疗溃疡性结肠炎临床疗效及对血清炎症因子水平的影响[J].中华中医药学刊,2017,35(6):1627-1629.
[12] 孙晋洁,孙永强.简体中文版炎症性肠病生存质量量表的信度及效度研究[J].护理研究:下旬版,2015,29(7):2581-2584.
[13] 张天涵,沈洪.溃疡性结肠炎及其中医辨证分型与炎症活动性指标的相关性分析[J].北京中医药大学学报,2019, 42(8):685-690.
[14] 王欣,陈爱霞,王佳,等.平溃健脾汤联合美沙拉嗪在溃疡性结肠炎治疗中的应用[J].山东医药,2018,58(26):44-46.
[15] 陈一鹏,韩丰.美沙拉嗪联合益生菌对老年中度活动期溃疡性结肠炎患者细胞因子水平的影响[J].中国老年学杂志,2019,39(10):2385-2387.
[16] 朱立伟,朱达坚.姜黄素联合美沙拉嗪治疗轻中度溃疡性结肠炎的临床观察[J].广东医学,2019,40(20):2921-2924.
[17] 杨薇薇.SASP加中药保留灌肠治疗溃疡性结肠炎64例[J].西部中医药,2019,32(1):102-105.
[18] 赵锁林,韩伟,刘甜,等.益气清热解毒化瘀法治疗溃疡性结肠炎的疗效及对高凝状态及炎性反应因子的影响[J].世界中医药,2018,13(9):2189-2192.
[19] 李骥,韦明明,费贵军,等.环孢素A治疗糖皮质激素抵抗的重度溃疡性结肠炎疗效观察[J].中华内科杂志,2017,56(4):279-283.
[20] 林崖.虎地肠溶胶囊联合美沙拉嗪治疗溃疡性结肠炎的临床研究[J].现代药物与临床,2019,34(9):2778-2781.
[21] 张莉,顾清,张璐,等.美沙拉嗪联合嗜热链球菌及复方谷氨酰胺对溃疡性结肠炎患者炎性因子及免疫功能的影响[J].川北医学院学报,2019,34(4):325-328.
[22] 周晓明,顾庆华.辨证分型中药内服结合外治治疗溃疡性结肠炎的临床疗效及对免疫功能的影响[J].世界中医药,2018,13(4):904-908,914.
[23] 林燕萍,叶柏,宁丽琴.叶柏运用古方治疗溃疡性结肠炎经验[J].辽宁中医杂志,2016,43(11):2277-2279.
[24] 赵欣,恽海峰,向桂玲,等.白头翁汤加减联合双歧杆菌制剂对大鼠溃疡性结肠炎的影响[J].中国实验方剂学杂志,2018,24(13):110-116.
[25] 张敏,鲁天瑜,王立群.仙白助运汤联合美沙拉嗪治疗肝郁脾虚型溃疡性结肠炎疗效观察[J].西部中医药,2019,32(11):95-97.
[26] 朱蕾蕾,李莉,顾志坚,等.基于数据挖掘的中医内服及灌肠治疗溃疡性结肠炎方药规律分析[J].上海中医药杂志,2019,53(7):10-14.
[27] 马乾章,李云,丁原全.白头翁汤加味联合美沙拉嗪缓释片治疗热毒炽盛型溃疡性结肠炎的临床疗效观察[J].海南医学院学报,2019,25(12):918-922.
[28] 范永强,张瑞芳,陈红霞,等.白头翁汤加减治疗大肠湿热型溃疡性结肠炎疗效观察[J].中国中西医结合外科杂志,2019,25(4):474-477.
[29] 缪志伟,王晓瑜,严晶,等.白头翁汤加减联合美沙拉嗪治疗溃疡性结肠炎的Meta分析[J].上海中医药杂志,2018,52(7):16-21,25. |
|
|
|